Recommended daily dosage and treatment regimen of Revumenib

Revumenib (Revumenib) is a drug that selectively inhibits mixed lineage leukemia (MLL, or KMT2A) rearranged or NPM1mutated Menin inhibitors of important oncogenic mechanisms in acute leukemia. The drug interferes with the interaction between Menin and MLL fusion protein, thereby blocking the signaling pathway that causes the continued proliferation of leukemia cells. In treatment, reasonable dosage and course design are crucial for efficacy and safety.

Based on clinical studies (such as the AUGMENT-101 trial) and early FDA recommendations, the recommended adult dose of Revemenib is 163 mg taken orally twice daily each time, and continuous 28 days constitutes a course of treatment. This dose is based on an empty stomach or a low-fat diet to ensure consistent drug absorption. It should be noted that this dose is the recommended starting dose. If the patient takes a strong CYP3A4 inhibitor or has liver dysfunction, the dose may need to be adjusted.

In terms of treatment course, Revimenib, as a targeted molecular inhibitor, has a non-cytotoxic mechanism of action, so it requires a longer period of maintenance treatment to achieve its due efficacy. It is usually recommended to evaluate the initial efficacy after at least two consecutive courses of treatment (about 8 weeks). Some patients can observe signs of bone marrow remission at the end of the first 1 course of treatment. If the treatment is effective, the patient may need to continue long-term maintenance treatment, and undergo regular bone marrow examinations and molecular marker monitoring to guide treatment course adjustments.

In addition, while taking Revemenib, doctors will monitor the patient's blood routine, liver and kidney function, electrolyte levels, electrocardiogram QT interval and other indicators to prevent and manage potential adverse reactions, such as neutropenia, anemia, QT prolongation, etc. Overall, Revimenib has demonstrated strong targeting advantages and good tolerability in the treatment of MLL/KMT2A rearrangement and NPM1 mutant leukemia. However, dosage and treatment duration guidelines must be strictly followed to ensure a balance between safety and efficacy.

Reference materials:https://www.drugs.com/